Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed. It was a busy week with lots of news, have a look and see you next week for another update.
Clearmind Medicine Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol Consumption
The groups were then given varying daily doses of the new treatment, with intermittent access to alcohol and water. After two weeks, researchers found a significant reduction in alcohol consumption in mice receiving the treatment. The control group showed no statistical significant reduction. Clearmind expects to conduct FDA-regulated clinical trials with humans later this year.
Awakn Life Sciences Completes World’s First Ketamine Treatment Study for a Range of Behavioral Addictions
The results from the study indicate the desired effects via potentially novel mechanisms and these results merit a larger study and further exploration, which Awakn is now initiating. The study also supports Awakn’s Intellectual Property (IP) strategy and existing filed patent applications, positioning Awakn as a leading company in the behavioral-addiction therapeutic research and development industry. The company expects to update investors further on its IP strategy in the coming weeks.
Braxia Scientific Receives Health Canada Special Access Program Approval to Provide Psilocybin-Assisted Therapy for Depression in Ontario
Health Canada approval is for a patient with the indication of Major Depressive Disorder, in the absence of terminal medical illness or end of life distress. The approval marks Braxia’s first Special Access Program (SAP) approval for use of psilocybin in Ontario. To date Braxia’s experienced therapists have delivered psilocybin-assisted therapy treatments to 16 individuals with depression through its proprietary clinical trial commenced late 2021.
MindMed Releases Phase 1 Trial Results For Opioid Addiction
The Phase 1 results showed positive safety and tolerability results, the main objective of this phase of the trial process (and an important hurdle considering that natural Ibogaine has a history of adverse physical effects). According to MindMed, Phase 2a trial remains on track to start in Q2 2022.
Mydecine Announces Size of Public Offering
The company announced that pursuant to its previously announced best efforts overnight marketed offering, they will issue up to 3,478,260 units at a price of $1.15 per Unit (the “Issue Price”) for aggregate gross proceeds of up to $4 million. The offering is expected to close on or about May 25, 2022. Stay tuned for more on this, as it would be welcome news for the firm.
